<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680065</url>
  </required_header>
  <id_info>
    <org_study_id>MSA-101</org_study_id>
    <nct_id>NCT04680065</nct_id>
  </id_info>
  <brief_title>GDNF Gene Therapy for Multiple System Atrophy</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brain Neurotherapy Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brain Neurotherapy Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is&#xD;
      to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in&#xD;
      subjects with either a possible or probable diagnosis of Multiple System Atrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Up to 9 study participants meeting eligibility criteria will be randomized in a 2:1 fashion to receive either the investigational medicinal product or sham surgery in this Phase 1 trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) assessed clinically by physical and neurological examinations</measure>
    <time_frame>3 years</time_frame>
    <description>Number of TEAE and SAE's reported post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSA symptoms/signs as assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) and compared to placebo. UMSARS total scores range from 0-104 points with higher scores indicating greater severity of impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in striatal dopamine transporter binding as measured by [123-I] Ioflupane</measure>
    <time_frame>12 months</time_frame>
    <description>Percent and absolute change in ratio of specific to non-specific binding of 123I FP-CIT to DaT from baseline and compared to placebo by Single Photon Emission Computed Tomography (SPECT) dopamine transporter (DaT) imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the quality of life as measured by Multiple System Atrophy Quality of Life (MSA-QoL)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline and compared to placebo in the Multiple System Atrophy Quality of Life (MSA-QoL) scale. MSA-QoL is a self-reported questionnaire that measures MSA impact in day to day activities. Scale consists of 40 items with a five response option format (0 - no problem to 4 extreme problem) and a &quot;not applicable&quot; response option.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Surgery</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV2-GDNF gene therapy</intervention_name>
    <description>Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham (Placebo) Surgery</intervention_name>
    <description>Bilateral partial burr/twist holes without dural penetration</description>
    <arm_group_label>Placebo Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults 35-75 years of age (inclusive)&#xD;
&#xD;
          -  Diagnosed with MSA with sporadic, adult-onset (&gt;30 yo) with predominant parkinsonian&#xD;
             symptoms&#xD;
&#xD;
          -  Less than 4 years from clinical diagnosis of MSA with expected survival &gt; 3 years&#xD;
&#xD;
          -  Stable medication regimen&#xD;
&#xD;
          -  Ability to walk with or without an assistive device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of idiopathic Parkinson's disease or other neurological diseases&#xD;
&#xD;
          -  Myocardial sympathetic denervation inconsistent with an MSA diagnosis&#xD;
&#xD;
          -  Presence of dementia, psychosis, substance abuse or poorly controlled depression&#xD;
&#xD;
          -  Prior brain surgery (i.e. deep brain stimulator) or other brain imaging abnormalities&#xD;
&#xD;
          -  Receiving an investigational drug&#xD;
&#xD;
          -  History of cancer or poorly controlled medical conditions that would increase surgical&#xD;
             risk&#xD;
&#xD;
          -  Inability to tolerate laying flat in an MRI or allergy to gadolinium&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amber Van Laar, MD</last_name>
    <email>infoCNS@askbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Stoicea, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Scott</last_name>
      <email>GDNFMSA@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Nicolas Phielipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanaz Attaripour-Isfahani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ileana Rubio</last_name>
      <email>irubio@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Barba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>OSUgenetherapyresearch@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Aristide Merola, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J. Bradley Elder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Taylor Rogers</last_name>
      <email>Taylor.Rogers@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>David A Hinkle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSA</keyword>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Neurotrophic factor</keyword>
  <keyword>Growth factor</keyword>
  <keyword>Glial cell line-derived neurotrophic factor</keyword>
  <keyword>GDNF</keyword>
  <keyword>AAV</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

